BLISS GVS PHARMA LTD. - 506197 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Ms Aditi BhattDesignation :- Company Secretary and Compliance Officer Bliss GVS Pharma Ltd - 506197 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Press Release announcing that Kremoint Pharma Private Limited, India, a 70% subsidiary of Bliss GVS Pharma Limited (BGPL) has received a compliant certification from the U.S. Food and Drug Administration (FDA) that was based on the inspection conducted at the Company's facility located at M.I.D.C, Ambernath (East), Thane-District. We are enclosing a copy of the press release. This is for your information and record. BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited has received request for issue of duplicate share certificates consequent to loss of share certificates from the shareholder. BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2019. Kindly take the same on record. Bliss GVS Pharma Ltd - 506197 - Closure of Trading Window
In accordance with reference to the circulars issued by BSE vide Circular no. LIST/COMP/01/2019-20 and NSE vide Circular no. NSE/CML/2019/11 dated April 2, 2019 and in complying with the aforesaid circulars and pursuant to SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 and in terms of Company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, we wish to inform you that, the Trading window for dealing in securities/shares of the Company will remain closed for all the Designated Persons and their immediate relatives of the Company with effect from Tuesday, October 01, 2019 until 48 hours after the announcement of the un-audited financial results of the Company for the quarter and half year end September 30, 2019. The Board meeting for approving the un-audited financial results for the quarter and half year end September 30, 2019 will be held on or before November 14, 2019. Bliss GVS Pharma Ltd - 506197 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Bliss GVS Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here BLISS GVS PHARMA LTD. - 506197 - Disclosure Of Revised Voting Results Of The 34Th Annual General Meeting Of Bliss GVS Pharma Limited Held On September 20, 2019
In continuation of our earlier letter dated 21.09.2019, we are submitting revised voting results of 34th Annual General Meeting of the Company held on Friday, September 20, 2019 in the prescribed format under Regulation 44 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Please acknowledge and take on record the same. BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited has received a request for issue of duplicate share certificates consequent to loss of share certificates. This is for your information and record. BLISS GVS PHARMA LTD. - 506197 - Voting Results Of The 34Th Annual General Meeting Of Bliss GVS Pharma Limited Held On September 20, 2019
In accordance with the Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith please find the voting results of 34th Annual General Meeting of the Company held on Friday, September 20, 2019 in the prescribed format along with the report of the Scrutinizer on e-voting and voting through ballot paper at the 34th Annual General Meeting. Please acknowledge and take on record the same. Bliss GVS Pharma Ltd - 506197 - Proceedings Of The 34Th Annual General Meeting For The Financial Year 2018-2019
Pursuant to Clause 13 of Para A of Part A of Schedule Ill of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") we enclosed herewith summary of proceedings of 34th Annual General Meeting of Bliss GVS Pharma Limited ("Company") held on Friday, September 20, 2019. Please acknowledged and take the same on record.